Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Uveal melanoma is the most common intraocular malignancy in adults and results in the death of 50% of the patients. Plasminogen activators (PA) are believed to facilitate tumor metastasis by promoting invasion of tissue barriers. The present study explored the possibility of preventing the metastasis of intraocular melanomas by disrupting plasminogen activator function through gene transfer. A replication-deficient adenovirus vector was used for the in vivo transfer of plasminogen activator inhibitor type 1 (PAI-1) cDNA. Intraocular injection of an adenovirus vector (AdCMV-PAI-1) expressing plasminogen activator inhibitor-1 resulted in: (1) the transduction of more than 95% of human and murine uveal melanoma cells in the eyes of nude mice; (2) a 50% reduction in the number of animals developing liver metastases; and (3) a 78% reduction in the metastatic tumor burden in animals that eventually developed metastases. In other experiments intravenous injections of AdCMV-PAI-1 resulted in transduction of normal liver cells and culminated in a sharp reduction in the incidence of metastases and a significant prolongation of host survival. The results support the feasibility of disruption of PA function through gene transfer as a therapeutic strategy for preventing metastases and prolonging host survival.
Ma
D
D
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas 75235-9057, USA.
Gerard
R D
RD
Li
X Y
XY
Alizadeh
H
H
Niederkorn
J Y
JY
D000260:Adenoviruses, Human / Q000235:genetics*; D000328:Adult; D000818:Animals; D003673:Defective Viruses / Q000235:genetics*; D005069:Evaluation Studies as Topic; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control / Q000556:secondary / Q000628:therapy; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009368:Neoplasm Transplantation; D017395:Plasminogen Activator Inhibitor 1 / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use; D014162:Transfection; D014183:Transplantation, Heterologous; D014604:Uveal Neoplasms / Q000473:pathology / Q000628:therapy*
D009363:Neoplasm Proteins; D017395:Plasminogen Activator Inhibitor 1; D011993:Recombinant Fusion Proteins; D010960:Plasminogen Activators